Research Article
Quality of Chronic Anticoagulation Control in Patients with Intracranial Haemorrhage due to Vitamin K Antagonists
| TREATMENT |
| Haemorrhage treatment N (%) | | (i) None | 16 (30.8%) | (ii) Vitamin K | 6 (11.5%) | (iii) Prothrombin | 0 (0%) | (iv) Prothrombin and vitamin K | 26 (50%) | (v) Surgical | 4 (7.7%) |
| Treatment at discharge N (%) | | (i) None | 10 (41.6%) | (ii) Antiplatelet agents | 3 (12.5%) | (iii) VKAs | 2 (8.3%) | (iv) VKAs and antiplatelet agents | 0 (0%) | (v) Dabigatran | 2 (8.3%) | (vi) Rivaroxaban | 0 (0%) | (vii) Apixaban | 0 (0%) | (viii) NOAC and aspirin | 0 (0%) | (ix) LAA closure | 5 (20.8) | (x) Prophylactic heparin | |
| Treatment at 3 months N (%) | | (i) None | 0 (0%) | (ii) Antiplatelet agents | 2 (9.1%) | (iii) VKAs | 2 (9.1%) | (iv) VKAs and antiplatelet agents | 0 (0%) | (v) Dabigatran | 4 (18.2%) | (vi) Rivaroxaban | 7 (31.8 %) | (vii) Apixaban | 2 (9.1%) | (viii) NOAC and aspirin | 0 (0%) | (ix) LAA closure | 3 (13.6%) | (x) Prophylactic heparin | 1 (4.5%) |
| Treatment changed 3 months after discharge. | 15/22 |
|
|
VKA: Vitamin K antagonist. NOAC: novel oral anticoagulant. LAA: left atrial appendage.
|